Drug Dosing in Pediatrics: Possible Approaches
https://doi.org/10.15690/vsp.v22i4.2593
Abstract
Drug dosing remains one of the topical issues of modern pediatrics. Insufficient number of clinical studies, vulnerable patient populations (preterm newborns, patients with renal and/or hepatic insufficiency, obesity), and high risk of polypragmasy create additional difficulties for practicing physicians. This review provides description of currently used approaches to drugs dosing in children. It has been shown that prognostic models should be used for solving drugs dosing issues regarding characteristics of young patients. Such models include: physiologically based pharmacokinetic modelling; population pharmacokinetic analysis; model-based precision dosing; modeling and simulation approach; use of real world data; and pharmacogenetic testing-based dosing. These models use information from preclinical and clinical stu
Keywords
children,
dosing,
medications,
population pharmacokinetics,
physiologically based pharmacokinetic model,
clinical studies,
drug design
Supporting agencies: Not specified.
About the Authors
Alexey S. Kolbin
Pavlov First Saint Petersburg State Medical University; Saint Petersburg University
Russian Federation
Disclosure of interest:
Russian Federation
Saint Petersburg
Disclosure of interest:
None
Kseniya S. Radaeva
Pavlov First Saint Petersburg State Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Saint Petersburg
Disclosure of interest:
None
References
1. ICH Harmonised Guideline Pediatric Extrapolation E11A ICH Consensus Guideline. 2022. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-e11a-pediatric-extrapolation-step-2b_en.pdf. Accessed on July 22, 2023.
2. Food and Drug Administration Modernization Act of 1997: Text S.830. 105th Congress (1997-1998). In: Congress.gov. Available online: https://www.congress.gov/bill/105th-congress/senate-bill/830/text. Accessed on July 22, 2023.
3. Kolbin AS. Klinicheskaya farmakologiya dlya pediatrov: Tutorial. Moscow: GEOTAR-Media; 2020. 288 p. (In Russ).
4. The European Agency for the Evaluation of Medicinal Products, Human Evaluations Unit. Report on the experts round table on the difficulties related to the use of new medicinal products in children held on 18 December 1997. EMEA/27164/98 Rev. 1. London, 30 July 1998. Available online: https://www.ema.europa.eu/en/documents/report/report-experts-round-table-difficulties-related-use-new-medicinal-products-children-held-18-december_en.pdf. Accessed on July 22, 2023.
5. Best Pharmaceuticals for Children Act. Summary: Text S.3452. 107th Congress (2001-2002). In: Congress.gov. Available online: https://www.congress.gov/bill/107th-congress/senate-bill/1789/text. Accessed on July 22, 2023.
6. Pediatric Research Equity Act of 2003: Text S.650. 108th Congress (2003-2004). In: Congress.gov. Available online: https://www.congress.gov/bill/108th-congress/senate-bill/650/text. Accessed on July 22, 2023.
7. Namazova-Baranova L.S., Sadeqi N., Baranov A.A. Unanswered Questions in Pediatric Clinical Trials: Literature Review. Pediatric pharmacology. 2022;19(1):61-71. (In Russ.) https://doi.org/10.15690/10.15690/pf.v19i1.2375
8. Zavidova S., Namazova-Baranova L., Topolyanskaya S. CLINICAL TRIALS OF DRUGS IN PEDIATRICS: PROBLEMS AND ACHIEVEMENTS. Pediatric pharmacology. 2010;7(1):6-14.
9. Burckart GJ, van den Anker JN. Neonatal and Pediatric Dose Selection: Quo Vadis? J Clin Pharmacol. 2021;61(Suppl 1):S7-S8. doi: https://doi.org/10.1002/jcph.1888
10. Powell JR, Cook J, Wang Y, et al. Drug Dosing Recommendations for All Patients: A Roadmap for Change. Clin Pharmacol Ther. 2021;109(1):65-72. doi: https://doi.org/10.1002/cpt.1923
11. Elias GP, Antoniali C, Mariano RC. Comparative study of rules employed for calculation of pediatric drug dosage. J Appl Oral Sci. 2005;13(2):114-119. doi: https://doi.org/10.1590/s1678-77572005000200004
12. van Rongen A, Krekels EH, Calvier EA, et al. An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children: Towards Decision Tables. Expert Opin Drug Metab Toxicol. 2022;18(2):99-113. doi: https://doi.org/10.1080/17425255.2021.2027907
13. Momper JD, Mulugeta Y, Green DJ, et al. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007. JAMA Pediatr. 2013;167(10):926-932. doi: https://doi.org/10.1001/jamapediatrics.2013.465
14. Tegenge MA, Mahmood I. Age- and Bodyweight-dependent Allometric Exponent Model for Scaling Clearance and Maintenance Dose of Theophylline From Neonates to Adults. Ther Drug Monit. 2018;40(5):635-641. doi: https://doi.org/10.1097/FTD.0000000000000543
15. Holford N. Dosing in children. Clin Pharmacol Ther. 2010; 87(3):367-370. doi: https://doi.org/10.1038/clpt.2009.262
16. Johnson TN, Ke AB. Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line? J Clin Pharmacol. 2021;61 (Suppl 1):S83-S93. doi: https://doi.org/10.1002/jcph.1834
17. Calvier EA, Krekels EH, Valitalo PA, et al. Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade? Clin Pharmacokinet. 2017;56(3):273-285. doi: https://doi.org/10.1007/s40262-016-0436-x
18. Malik PRV, Temrikar ZH, Chelle P, et al. Pediatric Dose Selection for Therapeutic Proteins. J Clin Pharmacol. 2021;61(Suppl 1): S193-S206. doi: https://doi.org/10.1002/jcph.1829
19. Mahmood I, Tegenge MA. Spreadsheet-Based Minimal Physiological Models for the Prediction of Clearance of Therapeutic Proteins in Pediatric Patients. J Clin Pharmacol. 2021;61 (Suppl 1):S108-S116. doi: https://doi.org/10.1002/jcph.1846
20. Perry C, Davis G, Conner TM, Zhang T. Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview. Curr Pharmacol Rep. 2020;6(3):71-84. doi: https://doi.org/10.1007/s40495-020-00212-x
21. Salerno SN, Edginton A, Gerhart JG, et al. Physiologically-based pharmacokinetic modeling characterizes the CYP3A-mediated drug-drug interaction between fluconazole and sildenafil in infants. Clin Pharmacol Ther. 2021;109(1):253-262. doi: https://doi.org/10.1002/cpt.1990
22. Grimstein M, Yang Y, Zhang X, et al. Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology. J Pharm Sci. 2019;108(1):21-25. doi: https://doi.org/10.1016/j.xphs.2018.10.033
23. Gonzalez D, Sinha J. Pediatric Drug-Drug Interaction Evaluation: Drug, Patient Population, and Methodological Considerations. J Clin Pharmacol. 2021;61(Suppl 1):S175-S187. doi: https://doi.org/10.1002/jcph.1881
24. Smits A, Kulo A, van den Anker J, Allegaert K. The amikacin research program: a stepwise approach to validate dosing regimens in neonates. Exp Opin Drug Metabol Toxicol. 2017;13(2):157-166. doi: https://doi.org/10.1080/17425255.2017.1234606
25. Kalaria SN, Farchione TR, Uppoor R, et al. Extrapolation of Efficacy and Dose Selection in Pediatrics: A Case Example of Atypical Antipsychotics in Adolescents With Schizophrenia and Bipolar I Disorder. J Clin Pharmacol. 2021;61(Suppl 1):S117-S124. doi: https://doi.org/10.1002/jcph.1836
26. Tikhov MS, Shkileva KN. A modified Reed- Muench method of estimation in dose-effect relationship. Vestnik TvGU. Seriya: Prikladnaya Matematika = Herald of Tver State University Series: Applied Mathematics. 2019;(4):5-26. (In Russ). doi: https://doi.org/10.26456/vtpmk543
27. Khurana M. Renal Impairment in Pediatric Patients: Current Approaches to Drug Dosing. J Clin Pharmacol. 2021;61(Suppl 1): S161-S164. doi: https://doi.org/10.1002/jcph.1908
28. Zhang Q, Travis J, Rothwell R, et al. Applying the Noninferiority Paradigm to Assess Exposure-Response Similarity and Dose Between Pediatric and Adult Patients. J Clin Pharmacol. 2021;61(S1): S165-S174. doi: https://doi.org/10.1002/jcph.1885
29. Ramsey LB, Brown JT, Vear SI, et al. Gene-Based Dose Optimiza-tion in Children. Annu Rev Pharmacol Toxicol. 2020;60:311-331. doi: https://doi.org/10.1146/annurev-pharmtox-010919-023459
30. Hoshitsuki K, Fernandez CA, Yang JJ. Pharmacogenomics for Drug Dosing in Children: Current Use, Knowledge, and Gaps. J Clin Pharmacol. 2021;61(S1):S188-S192. doi: https://doi.org/10.1002/jcph.1891
31. Relling MV, Pui CH, Cheng C, Evans WE. Thiopurine methyltrans-ferase in acute lymphoblastic leukemia. Blood. 2006;107(2): 843-844. doi: https://doi.org/10.1182/blood-2005-08-3379
32. Hahn D, Fukuda T, Euteneuer JC, et al. Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and Pediatric Patients. J Clin Pharmacol. 2020;60(8): 992-998. doi: https://doi.org/10.1002/jcph.1592
33. Ward RM, Tammara B, Sullivan SE, et al. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). Eur J Clin Pharmacol. 2010;66(6):555-561. doi: https://doi.org/10.1007/s00228-010-0811-8
34. Khokhlov AL, Sychev DA. The concept of patient-oriented medicine and pharmacy. Patient-Oriented Medicine and Pharmacy. 2023;1(1):1-4. (In Russ). doi: https://doi.org/10.37489/2949-1924-0001
35. Decision of the Eurasian Economic Commission Council dated March 17, 2022 No. 36 “O vnesenii izmenenii v Pravila registratsii i ekspertizy lekarstvennykh sredstv dlya meditsinskogo primeneniya”. (In Russ).
36. Barrett JS, Barrett RF, Vinks AA. Status Toward the Implementation of Precision Dosing in Children. J Clin Pharmacol. 2021; 61(Suppl1):S36-S51. doi: https://doi.org/10.1002/jcph.1830
37. Jarugula P, Scott S, Ivaturi V, et al. Understanding the Role of Pharmacometrics-Based Clinical Decision Support Systems in Pediatric Patient Management: A Case Study Using Lyv Software. J Clin Pharmacol. 2021;61(Suppl 1):S125-S132. doi: https://doi.org/10.1002/jcph.1892
38. Kolbin AS, Belousov D.Yu, Zyryanov SK, et al. Issledovaniya real'noi klinicheskoi praktiki. Kolbin AS, ed. Moscow: Izdatel'stvo OKI; Buki Vedi; 2020. 208 p. (In Russ).
39. Gusev AV, Zingerman BV, Tyufilin DS, Zinchenko VV. Electronic medical records as a source of real-world clinical data. Real-World Data & Evidence. 2022;2(2):8-20. (In Russ). doi: https://doi.org/10.37489/2782-3784-myrwd-13
40. van den Anker J, Allegaert K. Considerations for Drug Dosing in Premature Infants. J Clin Pharmacol. 2021;61(Suppl 1): S141-S151. doi: https://doi.org/10.1002/jcph.1884.
41. Green FG, Park K, Burckart GJ. Methods Used for Pediatric Dose Selection in Drug Development Programs Submitted to the US FDA 2012-2020. J Clin Pharmacol. 2021;61(Suppl 1):S28-S35. doi: https://doi.org/10.1002/jcph.1853
42. Vinks AA, Barrett JS. Model-Informed Pediatric Drug Development: Application of Pharmacometrics to Define the Right Dose for Children. J Clin Pharmacol. 2021;61(Suppl 1):S52-S59. doi: https://doi.org/10.1002/jcph.1841
Review
For citations:
Kolbin A.S., Radaeva K.S. Drug Dosing in Pediatrics: Possible Approaches. Current Pediatrics. 2023;22(4):289-297. (In Russ.) https://doi.org/10.15690/vsp.v22i4.2593
Views:
905
Email this article 
